CLL | Tumor

CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.

Blood Cancer Survivors Should Not Rely on COVID-19 Antibody Tests to Determine Immunity

August 24th 2021, 1:00pm


Patients with blood cancers may be less likely to derive immunity from the COVID-19 vaccine, though antibody tests should not be the end-all-be-all in guiding their behavior.

BTK Inhibitors Are the Path Forward in Frontline CLL Treatment

August 19th 2021, 1:00pm


Patients with chronic lymphocytic leukemia should talk to their doctors about the use of BTK inhibitors, as they produced promising outcomes in multiple trials.

CLL Treatment Represents ‘Very Optimistic Area’ in Research

August 9th 2021, 9:00pm


Outcomes in patients with CLL continue to improve with the emergence of targeted drugs and immunotherapy.

Navigating Chronic Lymphocytic Leukemia Diagnosis and Staging

July 28th 2021, 9:00pm


Although CLL follows a different staging format than other cancer types, diagnosing the disease properly can open the doors for more effective treatment and management strategies.

Patients With Blood Cancer Less Likely to Produce COVID-19 Antibodies After Vaccination

July 26th 2021, 1:00pm


About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

Study Analyzes Quality of Life Research on Patients With CLL and Their Caregivers

July 22nd 2021, 6:00pm


More research is needed on how a chronic lymphocytic leukemia diagnosis can affect patients and their caregivers.

Novel BTK Inhibitor Well Tolerated in Patients with CLL, Other B-Cell Malignancies

July 21st 2021, 6:00pm


TG-1701 monotherapy or added to ublituximab and Ukoniq contributed to early complete responses in patients with B-cell malignancies.

Drug Duo Boosts Outcomes in Elderly Patients With CLL

July 18th 2021, 9:00pm


Fixed-duration Venclexta plus Gazyva produced longer remissions than chemoimmunotherapy in elderly patients with chronic lymphocytic leukemia and other comorbidities.

Imbruvica-Venclexta Combo Superior to Chlorambucil-Obinutuzumab for CLL

June 16th 2021, 9:00pm


The combination of Imbruvica with Venclexta significantly reduced the risk for progression or death by 78% compared with chlorambucil plus obinutuzumab.

Front-Line Imbruvica-Venclexta Combo May Induce Durable Responses in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

June 10th 2021, 1:00pm


Treatment with this combination was associated with encouraging clinical responses in this patient population.